RE: NICE #CYP2C19 draft recommendation out 17th May14 May 2023 10:53
Genedrive® MT-RNR1 ID Test receives positive final recommendation by NICE
NICE issues final guidance for use in the NHS through Early Value Assessment programme
genedrive plc (AIM:GDR), the point of care molecular diagnostics company, announces that, further to the Company's announcement on 9 February 2023, the UK's National Institute for Health and Care Excellence (NICE) has today ratified and finalised its recommendation following a public consultation process that the Genedrive® MT-RNR1 ID Kit can be used by the NHS. The review was conducted through NICE's Early Value Assessment (EVA) programme, which was designed to select and recommend new technologies that will make a real difference to patients and provide the most value for the NHS.
The positive outcome was based on a number of key conclusions, including that the Genedrive® MT-RNR1 ID Kit can quickly and accurately identify babies with the MT-RNR1 genetic variant who may be at risk of hearing loss if given aminoglycoside antibiotics, and that no other test is available to provide results quickly enough to inform decisions on antibiotic prescribing in emergency care. These conclusions support, and are a consequence of, the Company's strategy for the development of rapid molecular diagnostics for emergency care.
David Budd, CEO of genedrive plc, said: "We are appreciative of the thorough review conducted by the NICE team. The final report issued today entirely reflects the preliminary conclusion published in February. As we continue with commercial roll out and product adoption, the NICE EVA framework will give us the opportunity to support specific performance and impact data that NHS users and commissioners may look for in future guidance. NICE, whose guidance is formally applicable to the NHS in England and Wales, is an internationally respected health authority and the tools and data supplied in its review will be relevant to the rest of the United Kingdom and to the other international markets which we are now accessing."
Also:-
20 minutes into our 21st November 2022 Presentation David Budd did say that GDR are working with Independent Economic Modellers to develop a 'Spread sheet' or a 'straight forward analysis tool' that can illustrate very effectively the net savings to a Hospital, or a Hospital system or the NHS as a whole!!
Note this Presentation can be found in the Genedrive PLC website.
Sign In
Follow the stocks
